Cargando…

Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status

Background: Nivolumab efficacy in patients with non-small-cell lung cancer (NSCLC) and performance status (PS) of 2-4 is unclear. We aimed to compare survival, treatment efficacy, and safety in patients with NSCLC with poor PS who received nivolumab plus best supportive care (BSC) with those in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katsura, Hideyuki, Suga, Yukio, Araya, Tomoyuki, Kita, Toshiyuki, Yoneda, Taro, Tanaka, Nobuyoshi, Kawabata, Ayumi, Ishita, Sotoki, Mase, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584408/ https://www.ncbi.nlm.nih.gov/pubmed/31258716 http://dx.doi.org/10.7150/jca.31217

Ejemplares similares

Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
por: Kimura, Hideharu, et al.
Publicado: (2019)

Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
por: Matsumoto, Toshihiko, et al.
Publicado: (2020)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
por: Tada, Hiroe, et al.
Publicado: (2020)

Large lung mass lesion with spontaneous regression in a patient with IgG4‐related lung disease
por: Iwasaki, Kazuhiko, et al.
Publicado: (2022)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Clinical Implication of Performance Status in Patients with Hepatocellular Carcinoma Complicating with Cirrhosis
por: Nishikawa, Hiroki, et al.
Publicado: (2015)

Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer
por: Abbas, M. Nazim, et al.
Publicado: (2021)

The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer
por: Takegawa, Naoki, et al.
Publicado: (2023)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

Relapsed Myasthenia Gravis after Nivolumab Treatment
por: Mitsune, Ayumi, et al.
Publicado: (2018)

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
por: Ikoma, Tatsuki, et al.
Publicado: (2022)

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
por: Uhara, Hisashi, et al.
Publicado: (2022)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Radiotherapy for liver cancer
por: Fukumitsu, Nobuyoshi, et al.
Publicado: (2017)

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
por: Osa, Akio, et al.
Publicado: (2018)

Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
por: Ishiwata, Tsukasa, et al.
Publicado: (2017)

Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
por: Tahara, Makoto, et al.
Publicado: (2021)

METHYLATION STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE IN LUNG CARCINOMA CELLS
por: Gamou, Shinobu, et al.
Publicado: (1988)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
por: Hata, Hiroki, et al.
Publicado: (2020)

Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
por: Araya, Tomoyuki, et al.
Publicado: (2019)

Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report
por: Matsumoto, Ryu, et al.
Publicado: (2020)

Myasthenic crisis and polymyositis induced by one dose of nivolumab
por: Kimura, Toshihiro, et al.
Publicado: (2016)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods
por: Suga, Yukio, et al.
Publicado: (2018)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
por: Katsuya, Yuki, et al.
Publicado: (2023)

Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
por: Kudo, Fumiaki, et al.
Publicado: (2018)

Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study
por: Matsuoka, Hiroki, et al.
Publicado: (2021)

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
por: Hagi, Takaomi, et al.
Publicado: (2020)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab
por: Hayashida, Michikata, et al.
Publicado: (2022)

Comparison of Solid-Water Partitions of Radiocesium in River Waters in Fukushima and Chernobyl Areas
por: Takahashi, Yoshio, et al.
Publicado: (2017)

Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
por: Sato, Miyuki, et al.
Publicado: (2019)

Decreased expression of CDH1 or CTNNB1 affects poor prognosis of patients with esophageal cancer
por: Ishiguro, Hideyuki, et al.
Publicado: (2016)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m93j5bt477ina0lim33sho7tod